Education
About Us
Working with TipRanks
Follow Us
Innoviva Inc (INVA)
NASDAQ:INVA
INVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.33 - $21.28
Previous CloseN/A
Volume64.08K
Average Volume (3M)916.46K
Market Cap
$1.08B
Enterprise Value$1.41B
Total Cash (Recent Filing)$304.96M
Total Debt (Recent Filing)$192.03M
Price to Earnings (P/E)82.6
Beta0.50
Next Earnings
Apr 23, 2025EPS Estimate
0.33Last Dividend Ex-Date
Sep 08, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)0.21
Shares Outstanding62,675,545
10 Day Avg. Volume1,409,294
30 Day Avg. Volume916,464
Financial Highlights & Ratios
PEG Ratio1.12
Price to Book (P/B)N/A
Price to Sales (P/S)3.02
Price to Cash Flow (P/CF)4.60
P/FCF Ratio4.30
Enterprise Value/Market Cap1.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.92
Enterprise Value/Ebitda15.20
Forecast
1Y Price Target
$55.00Price Target Upside217.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Innoviva News
PremiumCompany Announcements
Innoviva Reports Strong Q3 Growth Amidst Strategic AdvancesPremiumPre-Earnings
Innoviva (INVA) Q3 Earnings Cheat Sheet
---
Ownership Overview
10.07% Insiders
31.39% Mutual Funds
20.01% Other Institutional Investors
4.73% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INVA FAQ
What was Innoviva Inc’s price range in the past 12 months?
Innoviva Inc lowest stock price was $14.32 and its highest was $21.28 in the past 12 months.
What is Innoviva Inc’s market cap?
Innoviva Inc’s market cap is $1.08B.
When is Innoviva Inc’s upcoming earnings report date?
Innoviva Inc’s upcoming earnings report date is Apr 23, 2025 which is in 29 days.
How were Innoviva Inc’s earnings last quarter?
Innoviva Inc released its earnings results on Feb 05, 2025. The company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.37 by -$0.11.
Is Innoviva Inc overvalued?
According to Wall Street analysts Innoviva Inc’s price is currently Undervalued.
Does Innoviva Inc pay dividends?
Innoviva Inc pays a Semiannually dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Innoviva Inc dividends here
What is Innoviva Inc’s EPS estimate?
Innoviva Inc’s EPS estimate is 0.33.
How many shares outstanding does Innoviva Inc have?
Innoviva Inc has 62,675,545 shares outstanding.
What happened to Innoviva Inc’s price movement after its last earnings report?
Innoviva Inc reported an EPS of $0.26 in its last earnings report, missing expectations of $0.37. Following the earnings report the stock price went down -0.491%.
Which hedge fund is a major shareholder of Innoviva Inc?
Currently, no hedge funds are holding shares in INVA
---
Innoviva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$55.00 (217.37% Upside)
$55.00 (217.37% Upside)
Blogger Sentiment
Bullish
INVA Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 53.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $28.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 12.5%
Last 30 Days ▼ 12.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.21%
12-Months-Change
Fundamentals
Return on Equity
3.42%
Trailing 12-Months
Asset Growth
7.40%
Trailing 12-Months
Company Description
Innoviva Inc
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
---
INVA Stock 12 Month Forecast
Average Price Target
$55.00
▲(217.37% Upside)
Technical Analysis
Best Analysts Covering INVA
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-2.00%
initiated a buy rating 19 days ago
Copying Louise Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -2.00% per trade.
---